Group 1 - The core viewpoint is that Guotai Junan Securities maintains an "overweight" rating for Weigao Co., Ltd. (01066) and sets a target price of HKD 7.84, as Weigao Blood Products plans to acquire 100% of Weigao Purui's shares, positioning itself as the controlling shareholder and flagship platform for medical devices within the group [2][3] - The acquisition is expected to be completed in the second half of 2026, with Weigao Blood Products currently holding 23.53% of Weigao Co. and 94.07% of Weigao Purui prior to the transaction [3] - The assessed value of Weigao Purui's 100% equity is estimated at CNY 8.511 billion, with a share issuance price of CNY 31.29 per share, leading to the issuance of 272 million shares, which will constitute 39.43% of the total post-issuance share capital [3] Group 2 - The upstream biopharmaceutical market is expanding rapidly, with a projected market size of CNY 21.2 billion in 2024 and a compound annual growth rate (CAGR) of 11.5% expected from 2024 to 2030, indicating significant opportunities for domestic substitution [4] - Weigao Blood Products has established a product line for upstream biopharmaceutical filtration, while Weigao Purui possesses extensive customer resources in the biopharmaceutical sector, suggesting potential synergies post-acquisition [4] - Following the transaction, Weigao Co. will hold 52.10% of Weigao Blood Products, becoming its controlling shareholder and further clarifying its position as the flagship platform for medical devices under the Weigao brand [5]